Interpreting Breast Cancer Survival Data by the Hazard Function: Remarkable Findings from Event Dynamics.

breast cancer hazard function microscopic metastasis acceleration recurrence dynamics tumor dormancy tumor homeostasis

Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
12 Sep 2020
Historique:
received: 08 07 2020
revised: 09 09 2020
accepted: 10 09 2020
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 15 5 2021
Statut: epublish

Résumé

The report addresses the role of the hazard function in the analysis of disease-free survival data in breast cancer. An investigation on local recurrences after mastectomy provided evidence that uninterrupted growth is inconsistent with clinical findings and that tumor dormancy could be assumed as working hypothesis to understand the clinical course of the disease. Additionally, it was deemed that the lag-time between primary tumor removal and tumor recurrence is dynamically dependent on the subclinical metastasis development within the host-tumor system and, therefore, may be informative about the biology of the disease. Accordingly, the hazard function, which estimates the event risk pattern through the time, was adopted to analyze survival data. The multipeak pattern of the hazard function suggested that the process metastasis development has discontinuous features. A new paradigm of breast cancer metastatic development was proposed, involving the notions of tumor homeostasis, tumor quiescence in specific metastatic microscopic phases and surgery-related acceleration of the metastatic process. All analyses by prognostic factors (e.g., by menopausal status) or treatment modalities (e.g., by adjuvant chemotherapy) or other parameters (e.g., site of metastasis), provided coherent data in agreement with the model. The hazard rate function allowed addressing several clinical questions including meaning of ipsilateral breast tumor recurrence (IBTR), oncologic effect of delayed breast reconstruction, surgery related metastasis acceleration, possible role of anti-inflammatory drugs and body mass index (BMI) to modulate the recurrence risk. We conclude that the hazard function is a powerful tool to investigate the post-surgical course of early breast cancer and other operable tumors and to make inferences on their biology.

Identifiants

pubmed: 32932597
pii: medicina56090468
doi: 10.3390/medicina56090468
pmc: PMC7559922
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Breast Cancer Res. 2019 May 2;21(1):57
pubmed: 31046808
Breast Cancer Res Treat. 1997 Sep;45(2):193-202
pubmed: 9342444
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
Breast Cancer Res Treat. 2002 Sep;75(1):65-72
pubmed: 12500935
Cancer Res. 2002 Apr 1;62(7):2162-8
pubmed: 11929839
J Thorac Oncol. 2012 Apr;7(4):723-30
pubmed: 22425921
Cancer Res. 1979 Oct;39(10):3861-5
pubmed: 476622
Breast Cancer Res Treat. 2001 Feb;65(3):217-24
pubmed: 11336243
Surgery. 1977 Oct;82(4):443-7
pubmed: 898021
Breast Cancer Res. 2007;9(2):R21
pubmed: 17341292
Breast Cancer Res Treat. 2016 Jul;158(1):169-178
pubmed: 27306422
J Clin Oncol. 1985 Oct;3(10):1418-31
pubmed: 4045529
Curr Opin Obstet Gynecol. 2003 Feb;15(1):1-8
pubmed: 12544495
Anesth Analg. 2010 Jun 1;110(6):1630-5
pubmed: 20435950
Lancet. 1991 Aug 10;338(8763):327-31
pubmed: 1677695
Breast Cancer Res Treat. 2012 Jul;134(2):881-8
pubmed: 22622810
Nat Rev Clin Oncol. 2018 Apr;15(4):205-218
pubmed: 29283170
Eur J Cancer. 2017 Dec;87:10-20
pubmed: 29096156
J Natl Cancer Inst. 2000 Feb 16;92(4):347-8
pubmed: 10675389
Ann Plast Surg. 2008 Jul;61(1):11-8
pubmed: 18580143
Breast Cancer Res. 2013;15(5):R98
pubmed: 24148581
APMIS. 2008 Jul-Aug;116(7-8):730-41
pubmed: 18834415
J Clin Oncol. 2004 Jan 1;22(1):102-7
pubmed: 14701771
J Surg Oncol. 1990 Mar;43(3):181-8
pubmed: 2179631
Breast Cancer Res. 2004;6(6):R689-96
pubmed: 15535851
Nat Med. 1995 Feb;1(2):149-53
pubmed: 7585012
J Natl Cancer Inst. 2018 Oct 1;110(10):1115-1122
pubmed: 29718396
J Natl Cancer Inst. 1994 Jan 5;86(1):45-8
pubmed: 8271282
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643230
Future Oncol. 2016 Mar;12(5):647-57
pubmed: 26880385
Chin J Cancer Res. 2013 Feb;25(1):22-31
pubmed: 23372338
Breast. 2018 Aug;40:131-135
pubmed: 29772517
Breast Cancer Res Treat. 1996;41(2):177-85
pubmed: 8944336
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):800-9
pubmed: 22426147
J Clin Oncol. 1999 Jan;17(1):101-9
pubmed: 10458223
BMC Cancer. 2014 Jun 02;14:392
pubmed: 24890689
Eur J Cancer. 1977 Aug;13(8):839-45
pubmed: 908345
Ann Oncol. 1997 Nov;8(11):1075-80
pubmed: 9426326
Lancet. 1989 Oct 21;2(8669):949-52
pubmed: 2571865
Br J Surg. 2011 May;98(5):659-66
pubmed: 21312190
Ann Oncol. 2008 Nov;19(11):1821-8
pubmed: 18550576
Ann Oncol. 2005 Sep;16(9):1449-57
pubmed: 15956037
Eur J Cardiothorac Surg. 2016 Jun;49(6):1624-31
pubmed: 26792922
Med Oncol. 2013 Jun;30(2):514
pubmed: 23436014
J Natl Cancer Inst. 1999 Jan 6;91(1):80-5
pubmed: 9890174
Biochem Biophys Res Commun. 2015 May 8;460(3):543-8
pubmed: 25824032

Auteurs

Romano Demicheli (R)

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.

William Hrushesky (W)

School of Pharmacy Columbia, University of South Carolina, Columbia, SC 29201, USA.
Department of Medicine, Division of Epidemiology and Biostatistics (Cancer Epidemiology), School of Medicine Charleston, Medical University of South Carolina, Charleston, SC 29405, USA.

Michael Retsky (M)

Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Elia Biganzoli (E)

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH